en · de · es · pt
selank-notes.peptides7501.com › Data › Background And Peptide Identity — Worked Examples

Background And Peptide Identity — Worked Examples

By Editorial Desk · published 2026-02-20 · last reviewed 2026-03-07 · Data

Everything below concerns Peptidase stability. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Updated 2026-03-07. Numbers and descriptions here follow the published literature rather than marketing material.

Background and Peptide Identity

Selank is a synthetic heptapeptide developed in Russia. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-residue chain built around the natural tetrapeptide tuftsin. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences first described the compound in the mid-1990s. The design combined the tuftsin core with an added Pro-Gly-Pro tail, a modification intended to extend the molecule's stability in biological fluids. Published work on the peptide has appeared mainly in Russian-language journals.

Reported activity for Selank centers on anxiolytic and nootropic effects. Russian clinical reports describe use in anxiety and in cognitive or attention-related complaints. Most of this evidence comes from studies conducted by the same research groups that developed the peptide. Independent replication in other countries remains limited, and no major Western regulatory agency has approved the compound for any indication. The gap between local reports and external verification is a recurring point in discussions of the peptide.

Tuftsin, the parent structure, is a naturally occurring immunomodulatory tetrapeptide released from the Fc region of immunoglobulin G by spleen enzymes. Selank extends this four-residue sequence with three additional amino acids. The stated rationale is that the added tail slows enzymatic breakdown and may influence receptor interactions. How the full heptapeptide behaves at the molecular level is not firmly established, and proposed mechanisms often involve indirect modulation of neurotransmitter or immune signaling rather than a single defined target.

Mechanism and Evidence Base

Proposed mechanisms center on modulation of the GABA system, but no single molecular target has been confirmed. Rodent studies report changes in GABA-A receptor expression and in the turnover of serotonin, dopamine, and norepinephrine in several brain regions. Increases in brain-derived neurotrophic factor and its receptor have also been described after repeated administration. These findings come largely from animal models, and the degree to which they describe human neurochemistry remains an open question. The mechanism is best characterized as multi-system and not fully resolved.

Pharmacokinetic data are limited. Like most short peptides, Selank is vulnerable to plasma and tissue peptidases, and its measured half-life in circulation is short, on a minutes scale. The Pro-Gly-Pro tail slows this degradation but does not eliminate it. Intranasal administration is the route described in most reports, with absorption through the nasal mucosa and a hypothesized path into the central nervous system that avoids the blood-brain barrier. Direct measurements of human brain exposure are unavailable, so distribution claims rest on inference from animal work.

Selank at a glance

PropertyValueNotes
Chemical classSynthetic heptapeptideModeled on tuftsin
Amino acid sequenceThr-Lys-Pro-Arg-Pro-Gly-ProSeven residues
Approximate molecular massAround 750 DaDepends on counter-ion and hydration
Common formsLyophilized powderAlso described as aqueous solution
Primary origin of researchRussian laboratoriesMid-1990s onward

Selank Origin and Chemical Identity

Selank is a synthetic heptapeptide developed in Russia as a structural analogue of tuftsin, a naturally occurring immunomodulatory tetrapeptide. Its sequence, Thr-Lys-Pro-Arg-Pro-Gly-Pro, keeps the tuftsin core at the N-terminus and appends a Pro-Gly-Pro tail. Researchers at the Institute of Molecular Genetics in Moscow synthesized the compound during the 1990s while searching for peptides with combined anxiolytic and immunomodulatory activity. The added tail was intended to resist enzymatic cleavage and prolong the molecule's presence in circulation.

The compound has a calculated molecular weight near 751.9 daltons and carries a net positive charge at physiological pH because of its arginine residue. It dissolves freely in water and in common aqueous buffers, and typically appears as a white or off-white lyophilized powder. The amide backbone makes the molecule susceptible to peptidases, which limits oral use and favors intranasal or parenteral routes. Nomenclature in the literature varies: the substance is also described by the sequence abbreviation TP-7 and by a Russian trade designation.

Related pages on this site

Selank Background and Peptide Chemistry

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed as a stabilized analogue of tuftsin, a naturally occurring tetrapeptide fragment derived from the immunoglobulin heavy chain. The additional Pro-Gly-Pro segment at the carboxyl terminus is intended to slow enzymatic cleavage. The compound is usually described in the literature as a synthetic peptide with anxiolytic and cognitive-related activity, a label that reflects a research context rather than an approved therapeutic category.

Most published work on selank originates from a small number of research groups in the Russian Federation. A large share of that record appears in Russian-language journals, which limits access for readers who rely on English-indexed databases. Independent replication by laboratories outside the original research network is sparse in publicly available sources. This concentration of origin and language is a frequently noted feature when the compound is summarized in broader reviews of synthetic peptides.

Origins and Proposed Mechanisms

Proposed mechanisms centre on modulation of the GABAergic system, with reports of altered expression of genes related to GABA-A receptor subunits and changed monoamine turnover. Some studies describe inhibition of enkephalinase, the enzyme that degrades endogenous enkephalins, which may prolong opioid peptide signalling. Effects on brain-derived neurotrophic factor and on cytokine expression have also been reported. These findings come largely from animal models and small human studies, and the precise primary target remains unresolved.

Published clinical evidence is limited. Most controlled trials were conducted in Russia, enrolled modest numbers of participants, and appeared in Russian-language journals, which restricts independent verification. Reported outcomes include lower anxiety scores, improved attention and memory measures, and changes in fatigue ratings. Reviews written in English note methodological limitations such as small samples and inconsistent endpoints. Whether the compound produces clinically meaningful benefit relative to established anxiolytics is therefore an open question rather than an established finding.

Reference notes

== See also == Lysergamide § Related compounds Substituted isotryptamine List of investigational hallucinogens and entactogens List of miscellaneous 5-HT2A receptor agonists Non-hallucinogenic 5-HT2A receptor agonist BOL-148 (2-bromo-LSD) and SPT-348 SDZ SER-082 DLX-0002700 LEK-8829 LSD-Quinoline

Granin (chromogranin and secretogranin) is a protein family of regulated secretory proteins ubiquitously found in the cores of amine and peptide hormone and neurotransmitter dense-core secretory vesicles.

=== Basicity === Pyridines are Bronsted base and Lewis bases. The pKa values of their protonated forms are between 9.5 and 15.5. Comparatively strong bases include 2,3-diaminopyridine (pKS value of the protonated form: 15.26) and 2,4,6-collidine (15.0). Rather weak bases include 3-chloropyridine (9.56) and 2-methoxypyridine (9.94). For the base pyridine itself, the value of 12.53 lies in the middle of this range. The pKS values are similar for protonated 2-methylpyridine (13.28) and 2,2'-bipyridine (12.27). Pyridine is significantly less basic than the structurally related but saturated piperidine.

Sources: en.wikipedia.org

Notes from published material

== See also == History of atomic theory History of molecular theory History of crystallography before X-rays Geometrical crystallography before X-rays Physical crystallography before X-rays Timeline of chemistry Timeline of crystallography

=== 26 February === According to a Russian source, border clashes between Belarus and Ukraine resulted in the death of one Belarusian soldier. A Russian Beriev A-50U plane at the Machulishchy air base was said to have been destroyed by Belarusian partisans. However, satellite imagery of the Machulishchy air base from 28 February showed the sole A-50 located there still largely intact.

Fujirebio is a Japanese multinational in vitro diagnostics (IVD) company, founded in 1950 and headquartered in Tokyo, Japan. The company develops, manufactures, and markets IVD testing products — including reagents, instruments, and software — for clinical diagnostics and research use. Fujirebio operates offices in Asia, Europe, and the United States, and maintains a broad international distribution network, with manufacturing facilities in Japan, Europe, and the United States. The company employs more than 1,400 people globally. Fujirebio operates an open business model in which it develops novel biomarkers and diagnostic content, validates them using its own fully-automated Lumipulse® chemiluminescent enzyme immunoassay (CLEIA) platform, and distributes them globally through partnerships and a Contract Development and Manufacturing Organization (CDMO) model — providing development, manufacturing, and regulatory services to third-party diagnostic companies. The company’s principal areas of expertise include oncology, infectious diseases, and neurological disorders. In May 2025, Fujirebio received FDA 510(k) clearance for the Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio test, the first FDA-cleared blood-based IVD test to aid in identifying amyloid pathology associated with Alzheimer’s disease. In 2022, Fujirebio acquired ADx NeuroSciences, a Belgian biotech company specializing in neurological biomarker research, for €40 million. Fujirebio is a consolidated subsidiary of H.U. Group Holdings, Inc.

Sources: en.wikipedia.org

Further detail

The practice of reading a sentient's mind without permission (something the Culture is technologically easily capable of) is strictly taboo. The whole plot of Look to Windward relies on a Hub Mind not reading an agent's mind (with certain precautions in case this rule gets violated). Minds that do so anyway are considered deviant and shunned by other Minds (see GCU Grey Area). At one point it is said that if the Culture actually had written laws, the sanctity of one's own thoughts against the intrusion of others would be the first on the books. This gives some measure of privacy and protection; though the very nature of Culture society would, strictly speaking, make keeping secrets irrelevant: most of them would be considered neither shameful nor criminal. It does allow the Minds in particular to scheme amongst themselves in a very efficient manner, and occasionally withhold information.

=== Other possible solutions === Significant strides may be made relatively quickly if the focus shifts towards surgical subspecialties and their involvement in generated medical waste. Surgical specialties in particular have focused on infection control and thus have implemented single-use operative tools in their practices. One example of this can be seen within the practice of gastroenterology, where each endoscopy alone in the U.S. generates approximately 2.1 kg of disposable waste, of which 64% of the waste ended up in landfills. Thankfully, it appears that surgeons across the U.S. have agreed that their practice generates a high amount of waste and that a change needs to be implemented. A multi-center survey of 219 U.S. surgeons showed that 90% of them agreed strongly that waste of sterile surgical items is an issue and moreover, 95% of them agreed to a willingness to change their operating room workflow to reduce waste. Another focus that proves to be effective is reform around the policies that surround "red bag waste." Separation of medical waste is typically done via these bags and a narrative review out of U.S. operating rooms found that 90% of red bag waste, or the items found in the red waste bags, did not actually meet the criteria for pathologic or infectious waste. Initiative from corporations and hospitals is essential to creating a healthier environment, however, there are various methods in which involves action from the general population and would contribute to a clean air environment.

=== Targeting oxidative phosphorylation === Metabolic pathways can be targeted for clinically therapeutic uses. Within the mitochondrial metabolic network, for instance, there are various pathways that can be targeted by compounds to prevent cancer cell proliferation. One such pathway is oxidative phosphorylation (OXPHOS) within the electron transport chain (ETC). Various inhibitors can downregulate the electrochemical reactions that take place at Complex I, II, III, and IV, thereby preventing the formation of an electrochemical gradient and downregulating the movement of electrons through the ETC. The substrate-level phosphorylation that occurs at ATP synthase can also be directly inhibited, preventing the formation of ATP that is necessary to supply energy for cancer cell proliferation. Some of these inhibitors, such as lonidamine and atovaquone, which inhibit Complex II and Complex III, respectively, are currently undergoing clinical trials for FDA approval. Other non-FDA-approved inhibitors have still shown experimental success in vitro.

Sources: en.wikipedia.org

Frequently asked questions

What type of molecule is Selank?

Selank is a synthetic peptide made of seven amino acids. It is modeled on tuftsin, a natural tetrapeptide, with an added three-residue tail. It is not a small-molecule drug.

Where was Selank developed?

It originates from research in Russia, associated with the Institute of Molecular Genetics of the Russian Academy of Sciences. The first descriptions date to the mid-1990s. Most published studies come from Russian laboratories.

Is Selank found in nature?

No, Selank itself does not occur naturally. Its backbone is based on tuftsin, which is produced in the body, but the seven-residue version is a synthetic construct. It is supplied as a manufactured peptide.

What mechanisms are proposed for Selank?

Reports describe effects on GABA-A receptor expression, monoamine turnover, and neurotrophic factor levels. These are proposed mechanisms drawn mainly from animal models. No single molecular target has been established.

Network